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Abstract: Live-attenuated vaccines (LAV) are currently contraindicated during pregnancy,
given uncertain safety records for the mother–infant pair. LAV might, however, play an important
role to protect them against serious emerging diseases, such as Ebola and Lassa fever. For this
systematic review we searched relevant databases to identify studies published up to November 2019.
Controlled observational studies reporting pregnancy outcomes after maternal immunization with
LAV were included. The ROBINS-I tool was used to assess risk of bias. Pooled odds ratios (OR) were
obtained under a random-effects model. Of 2831 studies identified, fifteen fulfilled inclusion criteria.
Smallpox, rubella, poliovirus, yellow fever and dengue vaccines were assessed in these studies.
No association was found between vaccination and miscarriage (OR 0.98, 95% CI 0.87–1.10), stillbirth
(OR 1.04, 95% CI 0.74–1.48), malformations (OR 1.09, 95% CI 0.98–1.21), prematurity (OR 0.99,
95% CI 0.90–1.08) or neonatal death (OR 1.06, 95% CI 0.68–1.65) overall. However, increased odds
of malformations (OR 1.24; 95% CI 1.03–1.49) and miscarriage after first trimester immunization
(OR 4.82; 95% CI 2.38–9.77) was found for smallpox vaccine. Thus, we did not find evidence of harm
related to LAV other than smallpox with regards to pregnancy outcomes, but quality of evidence was
very low. Overall risks appear to be small and have to be balanced against potential benefits for the
mother-infant pair.
Keywords: live attenuated vaccines; safety; pregnant women; pregnancy outcomes
1. Introduction
Pregnancy induces immune modulation that renders women more susceptible to severe
manifestations of infectious diseases, some of which can potentially be prevented by vaccination,
e.g., influenza. In addition to protecting the mother, vaccination during pregnancy also serves as
a vehicle to protect the unborn or newborn child via high-titer transplacental antibodies which can
safeguard infants until active immunity through childhood vaccination has been established [1].
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Scientific evidence supporting the effectiveness of certain inactivated vaccines in pregnancy
is growing. Maternal immunization with tetanus, inactivated influenza and pertussis containing
vaccines is currently recommended in many countries based on extensive data supporting their safety,
and proven benefits for the mother–infant pair [1–3].
Live viral vaccines (LAV), on the other hand, can replicate in the host and are potentially capable
of causing viremia [4–6], conveying the risk of transplacental transmission to the developing fetus
with potential adverse consequences on pregnancy outcomes. Safety of vaccination during the first
trimester is of particular concern. During this period, women are more likely to be inadvertently
vaccinated in the context of mass campaigns, as they might not yet be aware of their pregnancies.
The theoretical risks associated with LAV have led to the exclusion of pregnant women from
clinical trials, hindering the development of high-quality evidence regarding potential benefits and
harms in this group. Despite the vast employment of LAV in diverse settings, current evidence comes
mainly from observational studies and national teratology registries [7].
The extensive use of smallpox vaccine in the 20th century brought about dozens of reported cases
of fetal vaccinia, resulting in stillbirth or neonatal death. The risk of fetal vaccinia has been estimated
at one per 10,000 to 100,000 immunizations during pregnancy [8,9].
With regards to rubella vaccine, there is evidence of vertical transmission and subclinical fetal
infection, as demonstrated by immunoglobulin M (IgM) titers in cord blood of exposed infants [10–12],
and more recently by molecular methods [13].
Oral poliovirus vaccine (OPV) has been widely used in mass immunization campaigns targeting
children and adults, including pregnant women. Transplacental infection with wild-type poliovirus
has been documented [14], and a fatal case of spinal cord damage after maternal immunization was
described [15]. However, fetal infectionwithOPVhasnot beendefinitely proven. Similarly, yellow fever
(YF) vaccine is capable of causing viremia but its potential for causing fetal infection is uncertain [16,17].
Major health benefits may be lost if maternal immunization is withheld on the basis of unproven
safety concerns, especially in the case of diseases that disproportionately affect pregnant women and
their offspring, and in outbreak scenarios. In recent years, the epidemics of Ebola and Zika have led
to an enhanced interest in the role of LAV in pregnant women and the ethical issues surrounding
their exclusion in clinical trials in such scenarios [18]. Furthermore, it is important to improve our
knowledge of the safety of vaccines that might be used in mass campaigns where pregnant women
may be inadvertently vaccinated, in order to inform future research and health policy.
Given the increasing likelihood that LAV could be used to combat emerging infectious disease
such as Ebola, Lassa and others, we aimed to assess the body of evidence evaluating the safety of
maternal immunization with LAV, and to identify the main areas of uncertainty where new studies
could be beneficial.
2. Materials and Methods
For this systematic review and meta-analysis we searched MEDLINE, EMBASE, Cochrane Central
Register of Controlled Trials (CENTRAL), Web of Science, Global Health, ClinicalTrials.gov, as well as
Open Grey and MedNar for published and unpublished studies from the inception of each database.
The search strategy was constructed in collaboration with a medical librarian (Table S1). The reference
list of all included articles was searched for additional studies. The initial search was conducted on
June 2019 and updated on 20 November 2019.
Primary studies of experimental and epidemiological study designs were deemed eligible
for inclusion if adverse pregnancy outcomes (i.e., miscarriage, stillbirth, neonatal death,
prematurity, low birth-weight, birth defects and congenital infection) were assessed in mother-infant
pairs exposed to immunization with one or more LAV during pregnancy or in the three months before
conception, and compared to mother-infant dyads with no exposure during or immediately before
gestation. Narrative reviews, case series, passive surveillance studies with no clear denominator,
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observational studies with no control group, and articles with unavailable full text were excluded
from the review. No language or geographic restrictions were applied.
The search results from each database were exported to Mendeley 1.19.4 and deduplicated.
Two reviewers (A.L. and D.B.) independently screened titles and abstracts, reviewed full texts of
potentially relevant articles against inclusion criteria, and extracted data into a previously designed data
collection form. Extracted data included study design, funding, country and setting, characteristics of
the exposed and control groups, potential confounders, number of participants, vaccine(s) administered,
trimester of pregnancy at vaccination, outcome definition and time points, number of events and
sample size for all prespecified outcomes, crude and adjusted estimates of effect and variables included
in adjusted analyses.
Included studies were independently evaluated by both reviewers using the ROBINS-I tool
(“Risk Of Bias In Non-randomized Studies—of Interventions”) [19]. The GRADE (Grading of
Recommendations Assessment, Development and Evaluation) approach was employed to assess
overall quality of evidence for the prespecified outcomes. Any discrepancies were solved by discussion
and consensus, consulting a third and fourth reviewer if necessary.
Data Analysis
A narrative synthesis was used to summarize the characteristics, results and internal validity
of included studies, by vaccine. Meta-analyses were carried out using Review Manager software
5.3 (Cochrane Collaboration, Oxford, UK) for outcomes for which studies were deemed comparable.
Pooled estimates of effect were obtained using the generic inverse-variance method under a random
effects model, and presented as odds ratios (OR) and their 95% confidence intervals (CI). Fixed zero-cell
correction was used for studies with no events in one or more groups. The degree of variability between
studies was assessed using the I2 statistic and heterogeneity was evaluated according to the Cochrane
Handbook guidelines.
Given the variety of vaccine types that we encountered and their potentially different effect
on pregnancy outcomes, we decided to do subgroup analyses by vaccine type, which had not been
pre-specified in the protocol. Sensitivity analyses were conducted excluding studies at critical risk of
bias. Given the greater susceptibility of the embryo to potential harmful effects of vaccines, we also
decided to perform sensitivity analyses for the association of vaccination in the first trimester of
pregnancy with miscarriage and congenital anomalies.
In addition to the studies included in the meta-analyses according to prespecified criteria,
cohorts with no comparison groupwere summarized to obtain further safety data, especially regarding
rare outcomes. The risk of congenital rubella syndrome (CRS) was calculated from studies of rubella
vaccination, including controlled and uncontrolled cohorts. The upper limit for the risk of CRS was
based on two-tailed 95% CI from the Poisson distribution.
There was no funding source for this study. The study protocol was registered with PROSPERO,
number CRD42019138360.
3. Results
The search strategy identified 2831 articles following the removal of duplicates, of which 15 studies
were included in the main body of this review: 12 cohorts (six retrospective, five prospective and one
historically-controlled), two case-controls, and one secondary data analysis from clinical trials (Figure 1).
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4028 records identified through database earching 
218 records identified through other sources 
162 ClinicalTrials.gov 
47 Cochrane Central Register of Controlled Trials 
9 reference sections of retrieved papers 
2882 records after duplicates removed 
2882 records screened 2757 Records excluded 
121 Full-text articles assessed for eligibility 
(15 full reports could not be retrieved) 
34 studies (from 50 reports) included 
in qualitative synthesis 
15 studies (from 18 reports) included in 
quantitative synthesis (meta-analysis) 
71 Full-text articles excluded 
12 Uncontrolled cohorts and 
pregnancy registries 
13 Case reports and case series 
10 Passive surveillance and 
pharmacovigilance studies 
2 Uncontrolled trials in women 
scheduled for abortion 
25 Reports with no primary data 
(Reviews, editorials or letters) 
3 Live vaccine outcomes mixed with 
inactivated vaccine data 
4 Not concerning pregnancy 
outcomes 
2 Multiple publications 
Figure 1. Flowchart showing the study selection process for the qualitative and quantitative synthesis.
An overview of the key characteristics of included studies is provided Table 1. All retrievable
articles were published in English and focused on populations from high and middle income countries
(see Appendix A). Sample size varies considerably, from a few dozens to over 9000 participants per
group. Only one was industry-funded [20]. Included studies reported on outcomes after immunization
with one of the following vaccines: smallpox (eight studies), rubella (three), OPV (two), YF (one),
and dengue (one).
3.1. Meta-Analysis of Pregnancy Outcomes
Meta-analysis was carried out for the outcomes of miscarriage, stillbirth, congenital anomalies,
prematurity, and neonatal death (See Table 2). Data on congenital infection and LBW was considered
inadequate for meta-analysis given the scarcity of studies reporting these outcomes, and the
heterogeneity in the methods of outcome assessment for congenital infection.
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Table 1. Characteristics of included studies.
Study Location Study Design Exposure Participants
Exposure in
1st Trimester
Previous
Immunity
Control Group Measured Outcomes
Abramowitz et
al. (1957) [21]
Cape Town,
South Africa
Retrospective
cohort
Smallpox vaccine
before 20 weeks
gestation
1121 vaccinated women
(510 with successful
vaccination *)
NR NR
201 women not
vaccinated during
pregnancy
Stillbirth, birth defects,
neonatal death.
Outcome definitions not
reported
Bar-Oz et al.
(2004) [22]
Toronto, Canada
Prospective
cohort
Rubella (RA 27/3)
vaccination ≤3
months before/after
conception
94 women counselled
about safety of rubella
vaccination during
pregnancy through a
telephone service
38 women NR
95 women counselled at
similar gestational ages
for non-teratogenic
exposures, not
vaccinated during
pregnancy
Miscarriage, birth defects,
congenital rubella
syndrome, neonatal
death. Outcomes
reported by mother and
physician ≥6 months
after expected DOB
Bellows et al.
(1949) [23]
New York, U.S.
Prospective
cohort
Smallpox vaccination
in pregnancy during a
mass vaccination
campaign
720 vaccinated women
(571 successful
vaccination *) ≤4
months pregnant at
admission to antenatal
clinic
247 women
210/720 with
accelerated
reaction,
suggestive of
partial
immunity
173 women admitted to
the same antenatal
clinics before 4 months
gestation, not
vaccinated during
pregnancy
Miscarriage (before 5
months), stillbirth (after 5
months), birth defects
(physical exam,
fundoscopy, X-ray,
follow-up for 12 months),
neonatal death
Bourke et al.
(1964) [24]
Dublin, Ireland
Prospective
cohort
Successful smallpox
vaccination * at any
stage of pregnancy
112 vaccinated women
attending antenatal
clinics in 4 hospitals
that account for >80%
of births in Dublin
54 women NR
448 women attending
the antenatal clinics on
the same day (4
adjacent charts), not
vaccinated during
pregnancy
Miscarriage, stillbirth,
birth defects (including
stillbirths), neonatal
death.
Outcome ascertained
from medical records.
Definitions not reported
Ebbin et al.
(1973) [25]
Los Angeles
County, U.S.
Retrospective
cohort
Rubella vaccination
during pregnancy or
within 3 months
before conception
60 vaccinated women
admitted to 7
participating hospitals
or referred from private
physicians
27 women
9/60
previously
susceptible,
rest unknown
47 controls from
hospital or private
practice, matched for
age, race, parity, sex of
the infant, and
private/non-private
hospital status
Miscarriage, congenital
infection (viral isolation
in products of conception
from abortion cases, or in
pharyngeal and rectal
swabs from live born
infants)
Greenberg et al.
(1949) [26]
New York City,
U.S.
Retrospective
cohort
Smallpox vaccination
in 1st trimester of
pregnancy during a
mass campaign
4172 † infants born to
vaccinated women in
participating hospitals
and health stations
4172 infants NR
2186 infants born to
non-vaccinated women
in the same period,
identified in
participating hospitals
and health stations
Birth defects (excluding
club foot, hydrocele,
inguinal hernia and
haemagiomas), LBW
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Table 1. Cont.
Study Location Study Design Exposure Participants
Exposure in
1st Trimester
Previous
Immunity
Control Group Measured Outcomes
Harjulehto et al.
(1993, 1994 and
1995) [27–29]
Greater Helsinki
Region, Finland
Retrospective
cohort
(population-based)
OPV vaccination
during mass
campaign; exposure
not determined at the
individual level
9508 ‡ births in the 3
hospitals that serve the
region, born of women
pregnant during the
mass vaccination
campaign
2984 § births
Most women
likely immune
(IPV included
in national
schedule)
12,126 live and
stillbirths reported in
the same hospitals from
July to December 1984
and 1986
Stillbirth (after 22 weeks
EGA), prematurity, SGA,
birth defects (BPA criteria,
including autopsies),
neonatal death (in the
first 7 days of life)
Liebeschuetz et
al. (1964) [30]
London, UK
Retrospective
cohort
Successful smallpox
vaccination * in
pregnancy during a
mass campaign
157 vaccinated women
attending a maternity
hospital during a
6-month period after
mass campaign
131 women
105/157 had
received
smallpox
vaccine in the
past
1657 women attending
the hospital during the
same period who were
not vaccinated or
“unsuccessfully”
vaccinated*
Miscarriage, stillbirth,
birth defects, fetal
vaccinia. Outcome
definitions not reported
Naderi et al.
(1975) [31]
Shiraz, Iran
Prospective
cohort
Successful smallpox
vaccination * in
pregnancy during
mass campaign
1542 infants of 1522
women attending
university hospital
clinics within 10
months after campaign
211 infants
All exposed
women
received
smallpox
vaccine in the
past
2045 infants of 2014
women not vaccinated
during pregnancy and
attending the same
clinics during the
following year
Miscarriage, stillbirth,
prematurity, birth defects,
clubfoot. Outcome
definitions not reported
Namaei et al.
(2008) [32]
Birjand, Iran
Prospective
cohort
Rubella vaccine ≤3
months before/after
conception, during a
mass campaign
106 vaccinated women
receiving antenatal care
and delivering at a
university hospital
71 women
Women with
previous
infection or
vaccination
were excluded
40 women not
vaccinated during
pregnancy. No details
of recruitment provided
Stillbirth, prematurity,
congenital infection
(serology in cord or infant
blood), congenital rubella
syndrome (CDC’s clinical
criteria)
Nishioka et al.
(1998) [33]
Uberlandia,
Brazil
Case control
Yellow fever (17D)
vaccination in
pregnancy during a
mass campaign §
CASES: 39 women
attended for
miscarriage at
university hospital,
with LMP ≥15 days
before mass campaign
NR NR
74 women living in the
same city who attended
the antenatal clinic at
the university hospital
Miscarriage (pregnancy
loss before 28 weeks
EGA)
Ornoy et al.
(1990 and 1993)
[34,35]
Israel
Historically-controlled
cohort
(population-based)
OPV vaccination
during a mass
campaign with 90%
coverage; exposure
not determined at the
individual level
Women attending
hospitals in West
Jerusalem within 4
months of campaign
(miscarriage) or ≤12
months after (birth
defects, LBW) ‡
N = 20,926 annual
births
NR
Most women
likely immune
(poliovirus
vaccine in
national
schedule since
1950s)
Women attending the
included hospitals
during the same period
in the previous year,
who were not
vaccinated during
pregnancy
N = 20,143 annual
births
Miscarriage (in relation to
the number of annual
births), birth defects (as
proportion of annual live
births), LBW (<2500 grs
birthweight). Outcomes
obtained from hospital
records
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Table 1. Cont.
Study Location Study Design Exposure Participants
Exposure in
1st Trimester
Previous
Immunity
Control Group Measured Outcomes
Ryan et al.
(2008) [36]
U.S.
Retrospective
cohort. (Dept. of
Defense
databases)
Smallpox vaccination
at any stage of
pregnancy
882 infants born during
2003-2004 to
active-duty military
women vaccinated
inadvertently during
pregnancy
672 women
NR, but
probably not
previous
immunity
(routine
vaccination
stopped in
1972)
23,685 infants born to
military women not
vaccinated against
smallpox; 6853 infants
born to active-duty
women vaccinated
before or after
pregnancy
Prematurity (birth before
37 weeks EGA), birth
defects (NBDPN
definitions used, records
up to 12 months of age
reviewed). Outcomes
defined using ICD-9-CM
codes
Saxen et al.
(1968) [37]
Finland Case control
Smallpox vaccination
before or during
pregnancy in the
context of a
country-wide
campaign
CASES 835 stillbirths
and 642 infants with
birth defects notified to
the National Board of
Health
NR
73% of
mothers in
study group
and 77% in
control group
previously
vaccinated
1477 infants born next
after
stillbirth/malformed
infants in the same
district
Stillbirth, birth defects
Outcome definitions not
reported
Skipetrova et al.
(2018) [20]
Several
countries
(mostly Latin
America)
Secondary
analysis of data
from clinical trials
Dengue (CYD-TDV)
vaccination during
pregnancy or <30
days before LMP
(“risk period”)
58 women
inadvertently
vaccinated during the
“risk period” in
CYD-TDV clinical trials
Most women
vaccinated
before or
shortly after
conception
NR
341 pregnant women
vaccinated outside the
“risk period”, 30
received placebo
during “risk period”,
179 received placebo
outside the “risk
period”
Miscarriage (pregnancy
loss before 20 weeks
EGA), stillbirth (fetal
death after 20 weeks
EGA)
NR =Not reported, NA =Not applicable, DOB = Date of birth, LBW = Low birth weight, EGA = Estimated gestational age, SGA = Small for gestational age, SD = Standard deviation,
IPV = Inactivated poliovirus, CDC = Centers for Disease Control and Prevention, LMP = Last menstrual period, BPA = British Pediatric Association, NBDPN =National Birth Defects
Prevention Network. * Successful vaccination against smallpox implies development of a vesicle or pustule at the inoculation site. † N = 4238 in exposed group and 2214 in control group
for assessment of LBW (longer follow-up to include all viable infants whose mothers were <3 months pregnant at vaccination). ‡ Exposure status (vaccination during pregnancy) was not
determined at the individual level. § Mass campaign after dengue outbreak with use of organophosphate fogging.
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Table 2. Summary of findings.
Vaccination during Pregnancy Compared with No Vaccination.
Patient or population: Pregnant women and their fetuses/infants.
Intervention: Administration of live vaccines during pregnancy or shortly before conception.
Comparison: No exposure to live vaccines during pregnancy or shortly before conception.
Outcomes Relative Effect (95% CI)
Number of
Participants (Studies)
Quality of the
Evidence (GRADE)
Comments
Miscarriage OR 0·98 (0.87 to 1.10) 17,763 (9 studies) Very low
Includes data on smallpox (4 studies), rubella (2),
OPV (1), dengue (1), and YF (1) vaccines.
Stillbirth OR 1·04 (0.74 to 1.48) 32,701 (9 studies) Very low
Includes data on smallpox (6 studies), rubella (1),
OPV (1), and dengue (1) vaccines.
Congenital anomalies OR 1.09 (0.98 to 1.21) 93,751 (12 studies) Very low
Includes data on smallpox (8 studies), rubella (2),
and OPV (2) vaccines.
Preterm birth OR 0.99 (0.90 to 1.08) 49,995 (5 studies) Very low
Includes data on smallpox (2 studies), rubella (2,)
and OPV (1) vaccines.
Neonatal death OR 1.06 (0.68 to 1.65) 24,499 (5 studies) Very low
Includes data on smallpox (3 studies), rubella (1),
and OPV (1) vaccines.
Miscarriage after 1st
trimester vaccination
OR 2.66|(0.73 to 9.64) 2832 (3 studies) Very low
Includes data on smallpox (1 study) and rubella (1)
vaccines.
GRADEWorking Group grades of evidence. High quality: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: We are moderately
confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: Our confidence in the
effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low quality: We have very little confidence in the effect estimate: The true effect
is likely to be substantially different from the estimate of effect.
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3.1.1. Miscarriage
Four studies on smallpox vaccine, two on rubella, and one each on OPV, YF, and dengue vaccine
reported onmiscarriage. Meta-analysis showed no association between immunization and spontaneous
abortion overall and for each type of vaccine (pooled OR: 0.98; 95% CI 0.87–1.10). No statistical
heterogeneity was detected across studies (I2 = 0%) (Figure 2a).
む
 
(a) 
 
(b) 
む
む
Figure 2. Meta-analysis of the association between maternal immunization and miscarriage. Forest
plots showing the effect of vaccination during pregnancy on the odds of miscarriage in all trimesters
(a) and in the first trimester (b), subgrouped by vaccine.
The analysis for exposure in the first trimester of pregnancy revealed a pooled OR of 2·66 (95% CI
0.73–9.64). However, the subgroup analysis showed a strong association between smallpox vaccination
and miscarriage (OR 4.82, 95% CI 2.38–9.77, p < 0·0001) as shown in Figure 2b.
Quality of evidence was rated as very low, given a critical risk of selection bias (Table S2).
When considering exposure to vaccination in the first trimester, downgrading was also granted for
imprecision. Funnel plot revealed no evidence of publication bias (Figure S1).
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3.1.2. Stillbirth
No association was found between vaccination and stillbirth (pooled OR: 1.04; 95% CI 0.74–1.48) in
thepooled analysis of nine studies, including six on smallpox, andone each on rubella, OPV, and dengue
vaccine (Figure 3). There was moderate statistical heterogeneity between studies (I2 = 45%, p = 0.07)
and quality of evidence was rated as very low due to serious risk of bias (Table S3). Funnel plot
revealed no evidence of publication bias (Figure S2).
む
 
む
む
む
む
Figure 3. Meta-analysis of the association between maternal immunization and stillbirth. Forest plot
showing the effect of immunization during pregnancy on the odds of stillbirth, subgrouped by vaccine.
3.1.3. Congenital Anomalies
Eight studies on smallpox vaccine, two on rubella, and two on OPV contributed data for
the meta-analysis of congenital anomalies, revealing no evidence of an association with maternal
immunization (pooled OR: 1.09; 95% CI 0.98–1.21); this also held true when considering only
pregnancies exposed to vaccination in the first trimester (pooledOR: 1.22; 95%CI 0.87–1.72), as depicted
in Figure 4a,b. Nonetheless, the subgroup analysis revealed an increase in the odds of congenital
anomalies after smallpox vaccination (OR: 1.24; 95%CI 1.03–1.49) and a tendency towards an association
with rubella vaccine, albeit with a very wide confidence interval (OR: 2.8; 95% CI 0.65–12.04).
No statistical heterogeneity was detected across studies for the overall effect of immunization on
congenital defects (I2 = 0%), but there was substantial heterogeneity (I2 = 77.4%) between different
vaccines when considering only first trimester immunization (p = 0·01 for subgroup differences,
Figure 4B). Quality of evidence was rated as very low, due to serious risk of bias (Table S4) and
suspicion of publication bias (Figure S3).
3.1.4. Preterm Birth
Five studieswere pooled in themeta-analysis for preterm birth, including two on smallpox, two on
rubella vaccine, and one on OPV. No association was found between vaccination and prematurity
(pooled OR: 0.99; 95% CI 0.90–1.08) overall and for each type of vaccine (Figure S4). No statistical
heterogeneity was detected across studies (I2 = 0%), but there was moderate heterogeneity between
subgroups (I2 = 42·7%). Quality of evidence was rated as very low as a result of serious risk of
bias (Table S5).
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Figure 4. Meta-analysis of the association of maternal immunization with congenital anomalies.
Forest plots showing the effect of immunization during pregnancy on the odds of congenital anomalies
in all trimesters (a) and in the first trimester (b), subgrouped by vaccine.
3.1.5. Neonatal Death
Three studies on smallpox vaccine, one on rubella, and one onOPVcontributed to themeta-analysis
of neonatal death, showing no association with vaccination (pooled OR: 1.06; 95% CI 0.68–1.65),
as depicted in Figure S5. No heterogeneity between estimates of effect was observed (I2 = 0%).
Quality of evidence was rated as very low due to serious risk of bias (Table S6) and imprecision.
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3.1.6. Sensitivity Analysis Excluding Studies at Critical Risk of Bias
Sensitivity analysis excluding four out of nine studies at critical risk of bias for the outcome of
miscarriage revealednoassociationwithvaccination (pooledOR: 0.97, 95%CI 0.86–1.09), consistent with
the findings of the analysis including all studies. In the case of miscarriage after first trimester
vaccination, all studies were at critical risk of bias and thus sensitivity analysis could not be conducted.
For the rest of outcomes there were no studies at critical risk of bias.
3.2. Uncontrolled Cohorts
Additionally, twenty-three uncontrolled cohorts [8,10–13,22,32,38–61] describing pregnancy
outcomes after maternal vaccination were retrieved in the literature search. No cases of fetal vaccinia
were found among 643 women vaccinated against smallpox [8,58,59], and rates of adverse pregnancy
outcomes were within expected limits, except for a high frequency of stillbirth among those vaccinated
in the first trimester [59] (Table S7).
Two controlled and twelve uncontrolled studies reported on the prevalence of CRS after maternal
immunization [10–13,22,32,38–43,60,61], as shown in Table S8. No cases were detected among
3918 infants, including 2303 born to women susceptible to rubella before vaccination. The upper
bound of the 95% CI for the risk of CRS is 0.09% for all infants, and 0.16% for those born to susceptible
women. These cohorts included participants receiving the Cendehill, HPV-77 and RA 27/3 viral strains,
which might differ in their fetotropic potential [10].
No signs of unexpected adverse pregnancy outcomes were found in four uncontrolled cohorts
of YF vaccine [16,17,62–64], except for an increase in minor dysmorphisms in a Brazilian cohort,
which was probably explained by detection bias [62]. Only one case of probable intrauterine infection
was detected among 422 infants tested for YF virus IgM (Table S9).
4. Discussion
According to the author´s knowledge, this is the first systematic review on the safety of the
administration of LAV during pregnancy. Available evidence comes mainly from cohorts of women
vaccinated against smallpox and, to a lesser extent, from observational studies regarding rubella,
OPV, YF, and dengue vaccines. With the exception of smallpox vaccine, maternal immunization with
these other vaccines shows no evidence of impact on pregnancy outcomes, but available evidence is of
very poor quality.
Smallpox vaccine is the only LAV clearly implicated in adverse pregnancy outcomes, given the
documented cases of fetal vaccinia, but, according to the available evidence, the risk of this severe
complication appears to be low. In the present review, an increase in the odds of birth defects was
detected and an association between vaccination in the first trimester and miscarriage was also
apparent. However, the studies evaluating this outcome were at critical risk of bias because women
were identified at prenatal clinics or hospitals, and early pregnancy losses were likely to be missed,
which could have decreased the effect estimate. Furthermore, some studies included all vaccinated
women, while others assessed only those considered as “successfully vaccinated”, i.e., subjects who
developed a cutaneous reaction. The proportion of women who underwent primary vaccination as
opposed to revaccination during pregnancy varied widely between studies, and preexisting immunity
could result in different responses to smallpox vaccine (see Table S7).
The largest studies included in this review were two population-based cohorts, comprising nearly
30,000 women, exploring the safety of OPV in the context of mass vaccination campaigns and showed
no increased risk of adverse pregnancy outcomes [27,35]. In neither of these studies was exposure to
vaccination determined at the individual level. However, mass campaign coverage was very high in
both cases, increasing the confidence in their findings.
Despite the clear teratogenic action of wild-type rubella virus and the evidence of intrauterine
infection in infants of women vaccinated during pregnancy, no cases of CRS have been documented in
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large cohorts of women inadvertently vaccinated during pregnancy or before conception in diverse
settings and with different vaccine strains, which might have different fetotropic and teratogenic
potential [10]. Maternal immunization with rubella vaccine does not appear to increase the risk of
adverse pregnancy outcomes according to the available evidence from populations of women with
varying degrees of previous immunity to rubella. However, the diversity of methods used to ascertain
susceptibility and congenital infection, including hemagglutination-inhibition, IgM and IgG assays,
IgG avidity tests, and viral isolation, could result in variable diagnostic accuracy.
Even though a total absence of risk cannot be proven, the likelihood of CRS is less than
one per 1000 exposed pregnancies, according to available evidence [10–13,22,32,38–42,60,61].
Therefore, women inadvertently vaccinated during pregnancy should be reassured and therapeutic
abortion would not be justified on the basis of a teratogenic potential of the vaccine.
The evidence regarding other LAV is even more scarce. In the case of YF vaccine, the only
controlled study suggested an increased odds of miscarriage among vaccinated women, but the
evidence for the association was weak. The mass vaccination campaign that provided the setting for
this study was conducted after a dengue outbreak where organophosphate insecticides had also been
used for vector control. Although reported exposure to organophosphates was similar between groups,
measurement was imprecise, and residual confounding cannot be ruled out.
Other pregnancy outcomes after YF vaccination have been described only in uncontrolled studies.
The largest of these cohorts followed 441 women inadvertently vaccinated in a mass campaign in
Brazil [16,62]; the frequency of stillbirths (0.7%) and preterm birth (7.8%) were similar or lower than
regional rates as reported by the authors. Major birth defects were found in 3.3% of 304 newborns.
Minor dysmorphisms were detected in 62 infants, a frequency greater than expected, but this was
attributed to evaluation bias. IgM antibodies were undetectable in blood samples from 341 infants, but
antibody persistence was detected in one of 37 children assessed after two years of age, raising the
possibility of intrauterine infection.
The only study analyzing the safety of maternal immunization with dengue vaccine suggested
a possible increase in the frequency of stillbirths [20], but there were only two events in the exposed
group, both in adolescent mothers. This association, however, should be furthered explored.
No controlled studies fulfilling the inclusion criteria were found for the live-attenuated influenza
vaccine (LAIV). Similarly, no studies on varicella-zoster virus (VZV) vaccine fulfilled inclusion criteria,
but data on 893 women accidentally vaccinated during or shortly before conception is available from
the Merck/CDC Pregnancy Registry [65,66]. The prevalence of congenital anomalies (2.1%) was similar
to that reported in the U.S. with no specific pattern of birth defects [67]. No cases of congenital varicella
syndrome were detected among 810 infants.
The live-attenuated viral vectored vaccine against Ebola (rVSV-ZEBOV) is currently being
administered to pregnant women as part of the ring vaccination strategy in Democratic Republic
of Congo [68]. This will provide an opportunity to evaluate pregnancy outcomes to better inform
decision-making in future outbreak scenarios.
Although the results presented in this manuscript are mostly reassuring, there are several
limitations which preclude drawing final conclusions regarding the safety of maternal immunization
with LAV. Besides the observational nature of the available evidence, most studies did not follow
participants from the time of vaccination, leading to incomplete ascertainment of early pregnancy loses,
which might include cases of congenital infection and malformations. Variable diagnostic criteria,
ancillary methods and follow-up for ascertainment of birth defects can result in varying degrees of
underreporting. The heterogeneity in study designs, settings, definitions and data collection methods
leads to challenges in the comparison of different studies. On the other hand, the wide variety of
countries and settings increases the generalizability to different populations. Furthermore, each LAV
might have a different effect on pregnancy outcomes, which might be obscured by obtaining pooled
effects. However, this was addressed by subgroup analyses which revealed an increased odds of
miscarriage and congenital anomalies only after smallpox vaccination.
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All but one of the included studies were considered at serious risk of bias due to confounding
for all outcomes, since most of them did not measure potential confounding factors or did not
control for them. Only the studies by Nishioka and Ryan provided an effect estimate adjusted for
confounding [33,36]. However, confounding domains were not measured validly in the first case,
and some important confounders were not controlled for in the second. Bar-Oz et al. controlled for
confounding by matching, but no information was provided on the methods used to measure these
potential confounders [22].
Four out of nine studies were considered at critical risk of selection bias for the outcome
of spontaneous abortion [24,25,30,31], because participants were selected among women attending
participating hospitals or clinics, thusmissing those receiving care in different facilities andmiscarriages
occurring before onset of prenatal care.
The findings from this literature review cannot be directly extended to other LAV given the
variable teratogenic potential of different vaccines. The use of modern technologies, such as viral
vectored vaccines and novel adjuvants, might also modify the safety profile of live vaccines available
in the near future. Furthermore, the power to detect a modest increase in the frequency of specific
types of malformations is low, so the association of maternal vaccination with birth defects cannot be
ruled out.
The development of new LAV that may target women of childbearing age, such as the viral
vectored candidates for the prevention of Zika [69,70], and the use of the existing ones in mass
vaccination campaigns or in response to outbreaks will need to be coupled with enhanced surveillance
of pregnant women and their infants, as well as standardized case definitions to better characterize
the impact of vaccination on the mother-offspring dyad [71]. Additionally, more accurate baseline
information on maternal and fetal outcomes in low and middle income countries (LMIC) is desirable
to make comparisons with appropriate local rates [71].
Furthermore, other factors need to be taken into accountwhen consideringmaternal immunization,
including implementation challenges and the need for integration with existing prenatal care services,
as well as the potential interference of maternal antibodies with the development of infant humoral
immune responses to vaccines in the first few months of life. This interference has been observed for
several vaccines but its clinical significance is still uncertain and might differ depending on the specific
antigen [72,73].
In summary, the risk of adverse pregnancy outcomes after maternal immunization with LAV
appears to be small. This information can support decision-makers in the planning of vaccination
campaigns that target women in the reproductive age, and may provide reassurance to healthcare
workers taking care of women inadvertently immunized with LAV during pregnancy.
Our findings may also inform pressing decisions regarding vaccination of pregnant women during
outbreaks. In this setting, benefits might exceed potential harms when the disease manifestations are
severe for pregnant women and/or their offspring and the probability of exposure is high, as is the case
with Ebola and Lassa Fever [74,75].
Inclusion of pregnant women in vaccine trials under conditions of enhanced safetymonitoring and
appropriate follow-up of mothers and infants has the potential to expand the benefits of immunization
to these populations. The views of pregnant women themselves need to be taken into account in
research design and policy making. Qualitative research on vaccine confidence [18,76] and willingness
to participate in clinical trials, conducted in different settings and geographic locations, can help
improve acceptance. We believe that pregnant women ought to be protected through research, not from
research, in order to move forward in the promotion of health equity.
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Appendix A. Qualitative Synthesis of Included Studies
Findings of the included studies reporting on pregnancy outcomes are summarized below,
grouped by vaccine.
Appendix A.1. Smallpox Vaccine
Three prospective and four retrospective cohorts, as well as one case control study fulfilled the
inclusion criteria. All were conducted between the 1940s and 1960s, except for one more recent cohort
published in 2008.
Bellows et al. (1949) conducted a prospective cohort of 720 women who presented to antepartum
clinics before the fourth month of pregnancy and who were vaccinated against smallpox during a mass
campaign in New York, and 173 unvaccinated controls [23]. Among those less than 5 months pregnant
at the moment of the vaccination campaign, 15 out of 428 (3.5%) exposedwomen and 4 out of 103 (3.9%)
control women experienced miscarriage (OR: 0.90; 95% CI 0.29–2.77). Stillbirths occurred in 23 of 705
(3.3%) pregnancies that reached the fifth month in the exposed group, compared to 4 out of 169 (2.4%)
in the control group (OR 1.39; 95% CI 0.47–4.08). Birth defects were documented in 3.3% and 2.4% of
births (OR: 1.39, 95% CI 0.47–4.08), and neonatal deaths in 1.6% and 0.6% in the vaccinated and control
groups respectively (OR: 2.69; 95% CI 0.34–21).
In another study carried out in New York, Greenberg et al. (1949) retrospectively studied
4172 infants born to mothers vaccinated in the first trimester of pregnancy and 2186 controls
identified in the same hospitals and time period [26], and found no evidence of increased risk of major
malformations among exposed newborns (0.7% versus 0.6%, OR: 1.25; 95% CI 0.65–2.40).
In a retrospective cohort in Cape Town, Abramowitz (1957) described the pregnancy outcomes
of 1121 women vaccinated in the first 20 weeks of pregnancy and 201 unvaccinated women [21],
finding no evidence of increased risk of stillbirth (1.9% versus 1.5%, OR: 1.26; 95% CI 0.37–4.26) or
neonatal death (1.4% versus 1.5%, OR: 0.90; 95% CI 0.26–3.13). Twenty-four (2.1%) exposed and three
(1.5%) unexposed infants were diagnosed with a congenital malformation (OR: 1.44; 95% CI 0.43–4.84).
Similarly, no evidence of increased risk of adverse pregnancy outcomeswas found by Liebeschuetz
(1964) in another retrospective cohort that included 157 vaccinated and 1657 unvaccinated or
unsuccessfully vaccinated (no reaction at injection site) women attending a maternity hospital during
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a 6-month period after a mass vaccination campaign in London [30]. The majority of exposed women
received the vaccine in the first trimester of pregnancy. The proportion of miscarriage (5.1% versus
4.5%, OR: 1.15; 95% CI 0.54–2.43) and stillbirth (2% versus 1.3%, OR: 1.53; 95% CI 0.45–5.19) was similar
between exposed and unexposed women. Birth defects were diagnosed in 3 out of 149 births in the
vaccine group and 22 of 1583 births in the control group (OR 1.46; 95% CI 0.43–4.93). No cases of fetal
vaccinia were diagnosed among all live or stillborn infants.
Bourke andWhitty (1964) studied 112 women exposed to smallpox vaccine during pregnancy and
448 unexposed mothers attending antenatal clinics in four hospitals in Dublin [24]. The proportion of
spontaneous abortion was the same in both groups (OR 1.0; 95% CI 0.11–9.04). Stillbirth was
more common among exposed women (3.6% versus 1.3%) but the confidence interval of the
odds ratio was compatible with no evidence for an association (OR 2.7; 95% CI 0.77–9.29).
Similarly, congenital anomalies were detected more frequently in the vaccine group (3 of 113
births) in comparison with the control group (3 of 449 births) but the estimate of effect had a wide
confidence interval including unity (OR 4.05; 95%CI 0.81–20.36). Two of the threemothers ofmalformed
infants in the exposed group received the vaccine late in pregnancy (23 and 27 weeks) making a causal
link unlikely. The frequency of neonatal deaths was 0.9% in both groups.
The pregnancy outcomes of 1522 women successfully vaccinated against smallpox at any stage
of pregnancy during a mass campaign in Iran were prospectively described by Naderi (1975) and
compared to 2014 unvaccinated women attending the same clinics during the following year [31].
All exposed women had received the smallpox vaccine in the past. Eighteen pregnancies in the
exposed group and twenty-one in the control group ended in miscarriage (OR: 1.14; 95% CI 0.60–2.14).
There were 23 stillbirths among vaccinated women and forty-eight among controls (OR: 0.63; 95%
0.38–1.04). The proportion of infants with malformations was similar between groups (1.4% versus
1.2%, OR: 1.17, 95% CI 0.66–2.08) but it was higher in the vaccine group when only those exposed in
the first trimester were taken into account (3.5% versus 1.2%, OR: 2.90; 95% CI 1.24–6.79). With regards
to specific defects, an increased risk for club foot was detected among infants exposed in the first
trimester in comparison to the unexposed group (1.5% versus 0.25%, OR: 6.06; 95% CI 1.44–25.57).
No cases of fetal vaccinia were detected in this cohort.
In a more recent study, Ryan et al. (2008) analyzed a cohort of infants born to active-duty military
women using data from the U.S. Department of Defense Databases [36]. Birth defects were diagnosed
in 40 of 882 infants exposed to smallpox vaccine during gestation and in 867 of 23,685 infants born to
unvaccinated mothers (OR: 1.25; 95% CI 0.77–1.40). Estimates of effect were similar when considering
only those exposed in the first trimester of pregnancy (OR: 1.24; 95% CI 0.85–1.81). These authors did
not find an increased risk of club foot in infants of vaccinated mothers. The prevalence of preterm
birth was similar between groups (7.5% versus 7.0%, OR: 1.07; 95% CI 0.83–1.38).
In the case control study by Saxen et al. (1968), 835 stillbirths and 642 newborns with congenital
anomalies notified to the National Board of Health in Finland were compared to 1477 infants born next
after the cases in the same district [37]. Birth defects were not significantly associated to vaccination
during pregnancy or shortly before conception (OR: 1.18, 95% CI 0.88–1.57) or to vaccination during
the first trimester (OR: 1.05; 95% CI 0.64–1.74). The odds of exposure to smallpox vaccine were lower
among stillbirths in comparison to controls (OR: 0.71; 95% CI 0.52–0.96).
Appendix A.2. Rubella Vaccine
Two prospective and one retrospective cohorts evaluated pregnancy outcomes after exposure to
rubella vaccine, with or without measles component. The rubella strain received by participants was
RA 27/3 in two of the studies, and is not reported in the other one.
A retrospective cohort conducted by Ebbin et al. (1973) in Los Angeles County included
60 women inadvertently vaccinated during pregnancy or less than 3 months before conception and
47 controls matched for age, race, parity, sex of the infant and private/non-private hospital status [25].
No association was found between vaccination and miscarriage, with three cases documented in
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each group (OR: 0.77; 95% CI 0.15–4.01). Fourteen pregnancies in the exposed group were interrupted
and rubella virus was isolated in two cases from products of conception. One of these isolates was
characterized as wild-type and the other as attenuated rubella virus, although molecular methods
were not yet available for confirmation. No virus was isolated in cultures of pharyngeal and rectal
swabs taken from 34 exposed infants.
Bar-Oz et al. (2004) prospectively followed 94 women who called a telephonic counselling service
for pregnant and lactating women in Toronto after being vaccinated against rubella within three
months before or after estimated conception, and 95 controls counselled at similar gestational ages for
non-teratogenic exposures [22]. No increased prevalence of miscarriage was found among vaccinated
mothers as compared to controls (6.4% versus 8.4%, OR: 0.74; 95% CI 0.25–2.3) but seven pregnancies
were interrupted due to fear of teratogenicity of rubella vaccine. No stillbirths were documented and
congenital anomalies were diagnosed in three newborns in each group, showing no association with
vaccination (3.7% versus 3.4%, OR: 1.08; 95% CI 0.21–5.5). There were no cases of congenital rubella
syndrome among 81 exposed newborns.
A prospective cohort conducted by Namaei et al. (2008) included 106 women vaccinated within
threemonths before or after conception during amass campaign in Iran, and 40 unexposed controls [32].
Women with a history of previous rubella infection or vaccination were excluded from the study.
One pregnancy in the exposed group (0.9%) and none in the control group ended in stillbirth.
The prevalence of prematurity was 7.5% among exposed newborns and 7.1% among the unexposed.
Birth defects were detected in 2 of 108 infants in the vaccine group and in none of the controls.
No evidence of congenital infection was found on the basis of serological essays performed in all
livebirths, and none of the children exhibited signs of CRS.
Appendix A.3. Oral Poliovirus Vaccine
Pregnancy outcomes after OPV vaccination have been assessed in two population-based studies.
Ornoy et al. (1993) conducted a historically-controlled study of women attending hospitals in West
Jerusalem and the Tel Hashomer hospital who were pregnant at the time of a mass vaccination
campaign, and a control group of pregnant women presenting at the participating hospitals during the
same period in the previous year [34,35]. The number of miscarriages was examined in relation to the
reported annual livebirths and no difference was found in the prevalence between the two groups
(OR: 0.96; 95% CI 0.85–1.09). With regards to birth defects, 243 were detected among 15,696 livebirths
in the exposed cohort and 204 among 15,201 livebirths in the controls (OR: 1.14; 95% CI 0.95–1.38).
Likewise, the prevalence of LBW was similar in the two groups (OR: 1.04; 95% CI 0.95–1.14).
After a mass vaccination campaign in Finland, Harjulehto et al. (1994) described the outcomes of
9508 live and stillborns in the Greater Helsinki region, born to women who were pregnant at the time
of the vaccination campaign, comparing them to 12,126 births reported in the previous and following
year in the same region [27–29]. No evidence of increased frequency of stillbirth (OR: 1.18; 95% CI
0.80–1.73), prematurity (OR: 0.93; 95% CI 0.84–1.04), neonatal death (OR: 1.01; 95% CI 0.61–1.68) or
birth defects (OR: 0.9; 95% CI 0.75–1.08) was detected.
Appendix A.4. Yellow Fever Vaccine
With regards to YF vaccine, a single case control study in the setting of a mass vaccination
campaign in Brazil fulfilled inclusion criteria. Nishioka et al. (1998) analyzed 39 women presenting
for miscarriage at a university hospital and 74 women who attended the antenatal clinic at the same
institution [33]. After adjusting for several confounders, the odds of exposure among cases was twice
as that of controls, but the evidence of an association between miscarriage and vaccination was weak
(OR: 2.29; 95% CI: 0.65–8.03, p = 0.20).
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Appendix A.5. Dengue Vaccine
The safety of dengue vaccine during pregnancy was analyzed in one industry-funded study
consisting of a secondary analysis of data from clinical trials of the chimeric tetravalent dengue vaccine
(CYD-TDV). Skipetrova et al. (2018) gathered information on 58 women inadvertently vaccinated
during pregnancy or shortly before conception and 550 women either vaccinated outside of this
“risk period” or participating in the placebo arm [20]. Seven percent of pregnancies ended in
miscarriage in both groups; stillbirth was more frequent among the exposed participants (2/52 versus
4/499) although confidence interval crossed one (OR: 4.95; 95% CI 0.88–27.7). No congenital anomalies
were diagnosed among 46 livebirths in the exposed group.
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